Nintedanib in Patients With Advanced Esophagogastric Cancer
Status:
Completed
Trial end date:
2020-04-22
Target enrollment:
Participant gender:
Summary
This is a phase II study of Nintedanib in patients with metastatic or recurrent
esophagogastric cancer. The goal of the study is to evaluate the efficacy of Nintedanib, an
orally available triple kinase inhibitor targeting the receptors of the vascular endothelial
growth factor (VEGF), platelet derived growth factor (PDGF), and fibroblast growth factor
(FGF) receptor pathways.